Chronic Myeloid Leukemia

  • Rüdiger Hehlmann

Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Table of contents

  1. Front Matter
    Pages i-x
  2. Bettina Balk, Alice Fabarius, Claudia Haferlach
    Pages 1-16
  3. Bradley Chereda, Junia V. Melo
    Pages 17-39
  4. Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Giuseppe Saglio
    Pages 41-54
  5. Michele Baccarani, Gabriele Gugliotta, Fausto Castagnetti, Simona Soverini, Gianantonio Rosti
    Pages 55-69
  6. Nicholas C. P. Cross, Andreas Hochhaus
    Pages 89-98
  7. Martin Höglund, Fredrik Sandin, Bengt Simonsson
    Pages 99-110
  8. Markus Pfirrmann, Michael Lauseker, Verena S. Hoffmann, Joerg Hasford
    Pages 111-128
  9. Benjamin Hanfstein, Martin C. Müller, Andreas Hochhaus
    Pages 129-145
  10. Rüdiger Hehlmann, Susanne Saußele, Richard T. Silver
    Pages 147-160
  11. Renuka Palani, Dragana Milojkovic, Jane F. Apperley
    Pages 161-175
  12. Moshe Talpaz, Jessica Mercer, Rüdiger Hehlmann
    Pages 207-230

About this book


This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. 


Chronic myeloid leukaemia BCR-ABL Tyrosine kinase inhibitors Philadelphia chromosome Fertility Hematopoietic stem cell transplantation Deep molecular response Interferon-alpha Survival Imatinib resistance Health economics

Editors and affiliations

  • Rüdiger Hehlmann
    • 1
  1. 1.Medizinische Fakultät MannheimUniversität HeidelbergMannheimGermany

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2016
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-33197-3
  • Online ISBN 978-3-319-33198-0
  • Series Print ISSN 2197-9766
  • Series Online ISSN 2197-9774
  • Buy this book on publisher's site